guest ::
| Home > Publications Database > Clinical and molecular characterization of isolated M1 disease in pediatric medulloblastoma: experience from the German HIT-MED studies. > print |
| Home > Publications Database > Clinical and molecular characterization of isolated M1 disease in pediatric medulloblastoma: experience from the German HIT-MED studies. > print |
| 001 | 163608 | ||
| 005 | 20240320115520.0 | ||
| 024 | 7 | _ | |a 10.1007/s11060-021-03913-5 |2 doi |
| 024 | 7 | _ | |a pmid:35190934 |2 pmid |
| 024 | 7 | _ | |a pmc:PMC8938370 |2 pmc |
| 024 | 7 | _ | |a 0167-594X |2 ISSN |
| 024 | 7 | _ | |a 1573-7373 |2 ISSN |
| 024 | 7 | _ | |a altmetric:123513577 |2 altmetric |
| 037 | _ | _ | |a DZNE-2022-00354 |
| 041 | _ | _ | |a English |
| 082 | _ | _ | |a 610 |
| 100 | 1 | _ | |a Obrecht, Denise |b 0 |
| 245 | _ | _ | |a Clinical and molecular characterization of isolated M1 disease in pediatric medulloblastoma: experience from the German HIT-MED studies. |
| 260 | _ | _ | |a Dordrecht [u.a.] |c 2022 |b Springer Science + Business Media B.V |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1655198547_924 |2 PUB:(DE-HGF) |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 500 | _ | _ | |a (CC BY) |
| 520 | _ | _ | |a To evaluate the clinical impact of isolated spread of medulloblastoma cells into cerebrospinal fluid without additional macroscopic metastases (M1-only).The HIT-MED database was searched for pediatric patients with M1-only medulloblastoma diagnosed from 2000 to 2019. Corresponding clinical and molecular data was evaluated. Treatment was stratified by age and changed over time for older patients.70 patients with centrally reviewed M1-only disease were identified. Clinical data was available for all and molecular data for 45/70 cases. 91% were non-WNT/non-SHH medulloblastoma (Grp3/4). 5-year PFS for 52 patients ≥ 4 years was 59.4 (± 7.1) %, receiving either upfront craniospinal irradiation (CSI) or SKK-sandwich chemotherapy (CT). Outcomes did not differ between these strategies (5-year PFS: CSI 61.7 ± 9.9%, SKK-CT 56.7 ± 6.1%). For patients < 4 years (n = 18), 5-year PFS was 50.0 (± 13.2) %. M1-persistence occurred exclusively using postoperative CT and was a strong negative predictive factor (pPFS/OS < 0.01). Patients with additional clinical or molecular high-risk (HR) characteristics had worse outcomes (5-year PFS 42.7 ± 10.6% vs. 64.0 ± 7.0%, p = 0.03). In n = 22 patients ≥ 4 years with full molecular information and without additional HR characteristics, risk classification by molecular subtyping had an effect on 5-year PFS (HR 16.7 ± 15.2%, SR 77.8 ± 13.9%; p = 0.01).Our results confirm that M1-only is a high-risk condition, and further underline the importance of CSF staging. Specific risk stratification of affected patients needs attention in future discussions for trials and treatment recommendations. Future patients without contraindications may benefit from upfront CSI by sparing risks related to higher cumulative CT applied in sandwich regimen. |
| 536 | _ | _ | |a 354 - Disease Prevention and Healthy Aging (POF4-354) |0 G:(DE-HGF)POF4-354 |c POF4-354 |f POF IV |x 0 |
| 588 | _ | _ | |a Dataset connected to CrossRef, PubMed, , Journals: pub.dzne.de |
| 650 | _ | 7 | |a Cerebrospinal fluid |2 Other |
| 650 | _ | 7 | |a Children |2 Other |
| 650 | _ | 7 | |a Medulloblastoma |2 Other |
| 650 | _ | 7 | |a Metastases |2 Other |
| 650 | _ | 7 | |a Radiotherapy |2 Other |
| 650 | _ | 2 | |a Cerebellar Neoplasms: drug therapy |2 MeSH |
| 650 | _ | 2 | |a Cerebellar Neoplasms: therapy |2 MeSH |
| 650 | _ | 2 | |a Child |2 MeSH |
| 650 | _ | 2 | |a Craniospinal Irradiation |2 MeSH |
| 650 | _ | 2 | |a Humans |2 MeSH |
| 650 | _ | 2 | |a Medulloblastoma: drug therapy |2 MeSH |
| 650 | _ | 2 | |a Medulloblastoma: therapy |2 MeSH |
| 650 | _ | 2 | |a Risk Factors |2 MeSH |
| 700 | 1 | _ | |a Mynarek, Martin |b 1 |
| 700 | 1 | _ | |a Hagel, Christian |b 2 |
| 700 | 1 | _ | |a Kwiecien, Robert |b 3 |
| 700 | 1 | _ | |a Spohn, Michael |b 4 |
| 700 | 1 | _ | |a Bockmayr, Michael |b 5 |
| 700 | 1 | _ | |a Bison, Brigitte |b 6 |
| 700 | 1 | _ | |a Pfister, Stefan M |b 7 |
| 700 | 1 | _ | |a Jones, David T W |b 8 |
| 700 | 1 | _ | |a Sturm, Dominik |b 9 |
| 700 | 1 | _ | |a von Deimling, Andreas |b 10 |
| 700 | 1 | _ | |a Sahm, Felix |b 11 |
| 700 | 1 | _ | |a von Hoff, Katja |b 12 |
| 700 | 1 | _ | |a Juhnke, B-Ole |b 13 |
| 700 | 1 | _ | |a Benesch, Martin |b 14 |
| 700 | 1 | _ | |a Gerber, Nicolas U |b 15 |
| 700 | 1 | _ | |a Friedrich, Carsten |b 16 |
| 700 | 1 | _ | |a von Bueren, André O |b 17 |
| 700 | 1 | _ | |a Kortmann, Rolf-Dieter |b 18 |
| 700 | 1 | _ | |a Schwarz, Rudolf |b 19 |
| 700 | 1 | _ | |a Pietsch, Torsten |0 P:(DE-2719)2812617 |b 20 |u dzne |
| 700 | 1 | _ | |a Fleischhack, Gudrun |b 21 |
| 700 | 1 | _ | |a Schüller, Ulrich |0 P:(DE-2719)9000979 |b 22 |u dzne |
| 700 | 1 | _ | |a Rutkowski, Stefan |0 0000-0002-5446-9571 |b 23 |
| 773 | _ | _ | |a 10.1007/s11060-021-03913-5 |g Vol. 157, no. 1, p. 37 - 48 |0 PERI:(DE-600)2007293-4 |n 1 |p 37 - 48 |t Journal of neuro-oncology |v 157 |y 2022 |x 0167-594X |
| 856 | 4 | _ | |y OpenAccess |u https://pub.dzne.de/record/163608/files/DZNE-2022-00354.pdf |
| 856 | 4 | _ | |y OpenAccess |x pdfa |u https://pub.dzne.de/record/163608/files/DZNE-2022-00354.pdf?subformat=pdfa |
| 909 | C | O | |o oai:pub.dzne.de:163608 |p openaire |p open_access |p VDB |p driver |p dnbdelivery |
| 910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 20 |6 P:(DE-2719)2812617 |
| 910 | 1 | _ | |a External Institute |0 I:(DE-HGF)0 |k Extern |b 22 |6 P:(DE-2719)9000979 |
| 913 | 1 | _ | |a DE-HGF |b Gesundheit |l Neurodegenerative Diseases |1 G:(DE-HGF)POF4-350 |0 G:(DE-HGF)POF4-354 |3 G:(DE-HGF)POF4 |2 G:(DE-HGF)POF4-300 |4 G:(DE-HGF)POF |v Disease Prevention and Healthy Aging |x 0 |
| 914 | 1 | _ | |y 2022 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |d 2022-11-08 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |d 2022-11-08 |
| 915 | _ | _ | |a Creative Commons Attribution CC BY 4.0 |0 LIC:(DE-HGF)CCBY4 |2 HGFVOC |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b J NEURO-ONCOL : 2021 |d 2022-11-08 |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0113 |2 StatID |b Science Citation Index Expanded |d 2021-01-28 |
| 915 | _ | _ | |a DEAL Springer |0 StatID:(DE-HGF)3002 |2 StatID |d 2021-01-28 |w ger |
| 915 | _ | _ | |a OpenAccess |0 StatID:(DE-HGF)0510 |2 StatID |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |d 2022-11-08 |
| 915 | _ | _ | |a IF < 5 |0 StatID:(DE-HGF)9900 |2 StatID |d 2022-11-08 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0160 |2 StatID |b Essential Science Indicators |d 2021-01-28 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1110 |2 StatID |b Current Contents - Clinical Medicine |d 2022-11-08 |
| 915 | _ | _ | |a Nationallizenz |0 StatID:(DE-HGF)0420 |2 StatID |d 2022-11-08 |w ger |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Clarivate Analytics Master Journal List |d 2022-11-08 |
| 920 | 1 | _ | |0 I:(DE-2719)1011009 |k Brainbank Unit Bonn |l Brainbank Unit Bonn |x 0 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a UNRESTRICTED |
| 980 | _ | _ | |a I:(DE-2719)1011009 |
| 980 | 1 | _ | |a FullTexts |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|